Guardant Health SEC Filings

Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported equity compensation activity and related tax withholding. On 01/15/2026, 17,379 restricted stock units vested and were converted into common stock at an exercise price of $0, increasing her directly held common shares to 38,369 immediately after the conversion. The same day, 8,808 of those shares were withheld and disposed of at $111.98 per share to cover tax obligations associated with the vesting, leaving her with 29,561 shares of common stock held directly. The vested restricted stock units stem from an award granted on February 26, 2024 that vests over three years, with 33% vesting on the one-year anniversary of January 15, 2024 and the remaining 67% vesting in equal annual installments over the following two years.

Guardant Health, Inc. reported that on January 11, 2026 it announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025. This information is provided in a press release that is furnished as Exhibit 99.1 to the report, rather than being formally filed, which limits how it is incorporated into other regulatory documents.

The company also disclosed that it will post the investor presentation used at the 2026 J.P. Morgan Healthcare Conference, scheduled for January 12, 2026, on its website under the Investors section. These updates are intended to give the market an early view of recent performance and the materials being shared with investors.

Guardant Health’s Chief People Officer, Terilyn J. Monroe, reported selling common stock in three transactions on January 7, 2026. She sold 6,311 shares at a weighted average price of $111.7521 per share, 3,632 shares at $112.6182 per share, and 88 shares at $113.4397 per share. After these sales, she held 20,990 shares of Guardant Health common stock directly. The prices reported are weighted averages for multiple trades within disclosed price ranges.

Guardant Health, Inc. insider Terilyn J. Monroe has filed a notice to sell 10,031 shares of Guardant Health common stock. The planned sale is to be executed through Charles Schwab & Co., Inc., on NASDAQ, with an indicated aggregate market value of $1,124,200.00 and 126,041,089 shares of Guardant Health common stock shown as outstanding.

The shares to be sold were acquired on 01/01/2026 through equity compensation, including 8,720 shares from a performance stock lapse and 1,311 shares from a restricted stock lapse, both from Guardant Health, Inc. The filing also shows that Monroe previously sold 55,167 Guardant Health shares on 12/01/2025 for gross proceeds of $5,846,164.00.

Guardant Health, Inc. director reports RSU vesting and share acquisition. On 12/17/2025, reporting person Manuel Hidalgo Medina acquired 232 shares of Guardant Health common stock at a price of $0 through the settlement of previously granted restricted stock units, reported with transaction code M.

The restricted stock units were granted on July 17, 2024 and vest over four years, with 25% of the shares vesting on the one-year anniversary of that date and the remaining 75% vesting monthly over the following three years. After this transaction, the reporting person beneficially owns 1,029 shares of common stock directly and 7,193 restricted stock units.

Guardant Health, Inc. director Musa Tariq disclosed a small sale of company stock. On 12/17/2025, the reporting person sold 116 shares of Guardant Health common stock at a price of $101.46 per share. After this transaction, the director beneficially owned 7,993 shares of Guardant Health common stock, held in direct ownership. This filing is a routine insider ownership update and does not describe any additional transactions or derivative securities.

Guardant Health, Inc. director reports routine vesting of restricted stock units. On 12/15/2025, a reporting person who serves as a director of Guardant Health, Inc. (ticker GH) acquired 250 shares of common stock at a price of $0 through the vesting and settlement of previously granted restricted stock units. After this transaction, the director beneficially owned 8,109 shares of common stock directly and 3,748 restricted stock units that remain outstanding.

The restricted stock units were originally granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting in equal monthly installments over the following three-year period.

Guardant Health, Inc. reported insider equity activity by its Chief Legal Officer, John G. Saia. On 12/15/2025, 1,020 restricted stock units were converted to common stock at an exercise price of $0, increasing his directly held common shares to 44,192 before related tax actions. On the same date, 535 common shares were withheld and disposed of at $102.67 per share to satisfy tax withholding obligations tied to the vesting of the restricted stock units, leaving him with 43,657 common shares held directly.

The derivative securities table shows that these transactions relate to a restricted stock unit award granted on June 9, 2023, covering common stock. After the reported conversion of 1,020 units, Saia continues to hold 2,039 restricted stock units, which vest over a three-year period, with 33% having vested on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.

Guardant Health, Inc. (GH) disclosed an insider equity transaction by its Chief Information Officer, Kumud Kalia. On 12/15/2025, 637 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units. On the same date, 323 shares were disposed of at $102.67 per share, with the company retaining these shares to satisfy tax withholding obligations related to the vesting. After these transactions, the reporting person beneficially owned 22,679 shares of common stock directly, along with 1,275 restricted stock units that remain outstanding and subject to future vesting.